|
![]() |
|
|
ReVia: profile and news
Revia (naltrexone) Gets an A as Treatment For Alcoholism May 2, 2006 Schuckit Addresses State-of-the-Art Addiction Treatments May 14, 2006 One of two available alcoholism drugs works-study May 2, 2006 Field of dreams? In Thorndale, those dreams are being realized May 10, 2006 Have a drinking problem? Why not try drugs! Apr 19, 2006 Drinking Problem? Try Drugs Apr 19, 2006 Older Drug Helps Alcoholics Abstain May 2, 2006 Reinventing Rehab Apr 19, 2006 Lawrence County takes county softball title Apr 24, 2006 Hubbard's golf continues to roll Athens softball team wins 40th ... Apr 19, 2006 Medley, Franks lead East Limestone to 22nd softball shutout of the ... Apr 27, 2006 Palm Beach County news briefs Apr 21, 2006 East Limestone takes county softball title Apr 23, 2006 Other information Indication For treatment of opioid type drug dependence. Pharmacology Naltrexone, a pure opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. It markedly attenuates or completely blocks, reversibly, the subjective effects of intravenously administered opioids. When co-administered with morphine, on a chronic basis, Naltrexone blocks the physical dependence to morphine, heroin and other opioids. In subjects physically dependent on opioids, Naltrexone will precipitate withdrawal symptomatology. Mechanism Of Action Naltrexone binds to the opioid mu receptor antagonistically, thereby preventing conventional opiate (heroin, morphine) drugs from binding and inducing opioid neural responses. The mechanism of action of Naltrexone in alcoholism is not understood; however, involvement of the endogenous opioid system is suggested by preclinical data. Naltrexone competitively binds to such receptors and may block the effects of endogenous opioids. Drug Category Anti-craving Agents; Depressants; Alcohol Antagonists; Opiate Antagonists; ATC:N07BB04 Brand Names/Synonyms CCRIS 3506; Celupan; HSDB 6750; N-Cyclopropylmethylnoroxymorphone; Naltrexona [Inn-Spanish]; Naltrexone; Naltrexone Hcl; Naltrexone [Usan:Ban:Inn]; Naltrexonum [Inn-Latin]; Revia; UM-792; Vivitrex Dosage Forms TABLET Absorption Not Available Interactions Interactions for Naltrexone: Studies to evaluate possible interactions between REVIA and drugs other than opiates have not been performed. Consequently, caution is advised if the concomitant administration of REVIA and other drugs is required. The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks. Lethargy and somnolence have been reported following doses of REVIA and thioridazine. Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics. In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged. Chemical IUPAC Name Not Available Chemical Formula C20H23NO4 Half Life 4 hours Drug Type Approved Drug # Accession No APRD00005 CAS Registry Number 16590-41-3 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |